X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cadila Healthcare with Pfizer - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs PFIZER - Comparison Results

CADILA HEALTHCARE    Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE PFIZER CADILA HEALTHCARE/
PFIZER
 
P/E (TTM) x 34.8 23.9 145.5% View Chart
P/BV x 9.0 3.8 235.7% View Chart
Dividend Yield % 0.7 0.9 80.1%  

Financials

 CADILA HEALTHCARE   PFIZER
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-16
PFIZER
Mar-16
CADILA HEALTHCARE/
PFIZER
5-Yr Chart
Click to enlarge
High Rs4542,724 16.7%   
Low Rs3051,611 18.9%   
Sales per share (Unadj.) Rs96.1440.9 21.8%  
Earnings per share (Unadj.) Rs14.948.7 30.5%  
Cash flow per share (Unadj.) Rs17.875.8 23.5%  
Dividends per share (Unadj.) Rs3.2015.00 21.3%  
Dividend yield (eoy) %0.80.7 121.9%  
Book value per share (Unadj.) Rs52.3462.9 11.3%  
Shares outstanding (eoy) m1,023.7445.75 2,237.7%   
Bonus/Rights/Conversions FV5:1--  
Price / Sales ratio x3.94.9 80.3%   
Avg P/E ratio x25.544.5 57.3%  
P/CF ratio (eoy) x21.328.6 74.4%  
Price / Book Value ratio x7.34.7 155.0%  
Dividend payout %21.530.8 69.8%   
Avg Mkt Cap Rs m388,45899,163 391.7%   
No. of employees `00015.42.9 534.5%   
Total wages/salary Rs m13,3172,758 482.9%   
Avg. sales/employee Rs Th6,371.16,981.7 91.3%   
Avg. wages/employee Rs Th862.4954.5 90.4%   
Avg. net profit/employee Rs Th986.1771.1 127.9%   
INCOME DATA
Net Sales Rs m98,37620,170 487.7%  
Other income Rs m941857 109.8%   
Total revenues Rs m99,31721,028 472.3%   
Gross profit Rs m23,8294,310 552.9%  
Depreciation Rs m3,0221,239 244.0%   
Interest Rs m4865 9,346.2%   
Profit before tax Rs m21,2623,923 541.9%   
Minority Interest Rs m-3000-   
Prior Period Items Rs m50-   
Extraordinary Inc (Exp) Rs m-2599 -25.3%   
Tax Rs m5,7161,794 318.5%   
Profit after tax Rs m15,2262,228 683.5%  
Gross profit margin %24.221.4 113.4%  
Effective tax rate %26.945.7 58.8%   
Net profit margin %15.511.0 140.1%  
BALANCE SHEET DATA
Current assets Rs m44,37616,299 272.3%   
Current liabilities Rs m34,0717,594 448.7%   
Net working cap to sales %10.543.2 24.3%  
Current ratio x1.32.1 60.7%  
Inventory Days Days5465 82.5%  
Debtors Days Days6226 242.1%  
Net fixed assets Rs m47,8968,622 555.5%   
Share capital Rs m1,024458 223.8%   
"Free" reserves Rs m48,74620,722 235.2%   
Net worth Rs m53,51921,180 252.7%   
Long term debt Rs m8,96425 35,856.0%   
Total assets Rs m100,16329,137 343.8%  
Interest coverage x44.7755.5 5.9%   
Debt to equity ratio x0.20 14,189.8%  
Sales to assets ratio x1.00.7 141.9%   
Return on assets %15.77.7 204.7%  
Return on equity %28.410.5 270.5%  
Return on capital %34.319.0 180.6%  
Exports to sales %45.30.1 76,095.7%   
Imports to sales %5.917.5 33.9%   
Exports (fob) Rs m44,53712 371,141.7%   
Imports (cif) Rs m5,8383,526 165.6%   
Fx inflow Rs m44,88152 86,894.5%   
Fx outflow Rs m9,069140 6,478.8%   
Net fx Rs m35,812-88 -40,543.4%   
CASH FLOW
From Operations Rs m19,9383,436 580.2%  
From Investments Rs m-9,039-6,991 129.3%  
From Financial Activity Rs m-9,527-619 1,539.6%  
Net Cashflow Rs m1,372-4,174 -32.9%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 63.9 -  
Indian inst/Mut Fund % 8.3 7.5 110.7%  
FIIs % 5.9 4.9 120.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 23.7 46.4%  
Shareholders   44,069 85,207 51.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   SUN PHARMA  MERCK LTD  GSK PHARMA  FULFORD INDIA  ORCHID PHARMA LTD  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Flat Note; Dr Reddy's & Lupin Surge over 2%(Closing)

Indian share markets continued to trade just above the dotted line in the afternoon session in a lackluster day of trading. At the closing bell, the BSE Sensex closed higher by 33 points.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Aug 22, 2017 03:36 PM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - ALEMBIC LTD COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS